Futura Medical PLC (GB:FUM)
LSE:FUM
Top Page
Futura Medical
(LSE:FUM)
Select Model
Select Model
Rating:52Neutral
Price Target:
1.50 p
▲(21.95% Upside)
Action:N/ADate:01/04/26
The score is held back most by the earnings call’s sharply reduced FY2025 outlook and short cash runway, plus weak technical trend signals. These risks are partially offset by the FY2024 profitability turnaround and a zero-debt balance sheet, though negative free cash flow keeps financial quality mixed.
Futura Medical (FUM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.66M
Dividend YieldN/A
Average Volume (3M)3.22M
Price to Earnings (P/E)―
Beta (1Y)0.81
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding581,327,760
10 Day Avg. Volume4,828,957
30 Day Avg. Volume3,220,377
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)10.67
Price to Sales (P/S)6.87
P/FCF Ratio-74.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£5.10M
Futura Medical Business Overview & Revenue Model
Company Description
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of...
How the Company Makes Money
Futura Medical makes money primarily by commercializing its ED topical gel (Eroxon/MED3000) via partnerships and distribution agreements rather than operating large-scale in-house sales forces across all markets. Key revenue streams include: (1) L...
Futura Medical Earnings Call Summary
Earnings Call Date:Sep 30, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 15, 2026
Earnings Call Sentiment Negative
The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.Positive Updates
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Negative Updates
Revenue Shortfall
Revenues of just over GBP 1 million for H1 2025 fell significantly below expectations, with full-year sales now expected to be between GBP 1.3 million and GBP 1.4 million, far below the initial GBP 5 million projection.
Read all updates
Q2-2025 Updates
Positive
Negative
R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.
Read all positive updates
Company Guidance
During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.Futura Medical Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.93M | 13.93M | 3.10M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.05M | 9.57M | 1.77M | -24.73K | -19.81K | -25.01K |
| EBITDA | -6.14M | 1.41M | -6.83M | -6.85M | -5.85M | -2.90M |
| Net Income | -6.29M | 1.29M | -6.51M | -5.85M | -4.96M | -2.41M |
Balance Sheet | ||||||
| Total Assets | 5.49M | 13.59M | 11.82M | 6.47M | 11.80M | 1.62M |
| Cash, Cash Equivalents and Short-Term Investments | 3.69M | 6.60M | 7.71M | 4.03M | 10.37M | 1.02M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.44M | 4.63M | 6.34M | 1.75M | 2.08M | 766.52K |
| Stockholders Equity | 3.05M | 8.96M | 5.48M | 4.72M | 9.72M | 853.54K |
Cash Flow | ||||||
| Free Cash Flow | -402.30K | -1.29M | -935.60K | -6.52M | -4.29M | -4.55M |
| Operating Cash Flow | 501.43K | 438.41K | 570.25K | -5.78M | -3.87M | -4.54M |
| Investing Cash Flow | -903.73K | -1.73M | -1.43M | -740.70K | -419.72K | -7.45K |
| Financing Cash Flow | 181.86K | 170.91K | 4.55M | 169.58K | 13.65M | 3.06M |
Futura Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £25.86M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
52 Neutral | £6.66M | -0.92 | -115.97% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £30.32M | -1.92 | -53.86% | ― | ― | ― | |
44 Neutral | £25.27M | -54.98 | -10.01% | ― | 283.74% | 78.57% | |
43 Neutral | £5.06M | -2.61 | -2.42% | ― | ― | ― | |
42 Neutral | £277.75M | -1.74 | -361.23% | ― | ― | ― |
* Healthcare Sector Average
GB:FUM
Futura Medical
1.15
-9.20
-88.93%
GB:AVCT
Avacta Group plc
63.50
28.00
78.87%
GB:OPTI
OptiBiotix Health
4.90
-10.35
-67.87%
GB:SBTX
SkinBioTherapeutics
9.75
-15.25
-61.00%
GB:POLB
Poolbeg Pharma Ltd.
4.30
1.55
56.36%
GB:AREC
Arecor Therapeutics PLC
68.50
26.00
61.18%
Futura Medical Corporate Events
Business Operations and StrategyProduct-Related Announcements
Futura Medical Secures Key US Patent Milestone for Eroxon and Women’s Sexual Health Product
Positive
Feb 5, 2026
Futura Medical has received a notice of allowance for a US continuation patent that will extend protection for its erectile dysfunction gel Eroxon, including derivative formulations such as Eroxon Intense, as well as its women’s sexual healt...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Futura Medical Lifts 2025 Revenue Guidance and Extends Cash Runway to Late 2026
Positive
Feb 4, 2026
Futura Medical reported that unaudited revenue for 2025 is expected to reach £1.7 million, ahead of earlier guidance, and year-end net cash stood at £3.4 million following a £2.75 million fundraise completed in November. The company...
Business Operations and StrategyProduct-Related Announcements
Futura Medical Reports Strong Early Data for WSD4000 Female Sexual Dysfunction Gel
Positive
Jan 12, 2026
Futura Medical has reported highly positive early feasibility results for WSD4000, its topical gel prototype for female sexual dysfunction, in a 12-patient study that showed statistically and clinically significant improvements on the Female Sexua...
Regulatory Filings and Compliance
Futura Medical Confirms Total Voting Rights at 581.3 Million Shares
Neutral
Dec 31, 2025
Futura Medical has confirmed that its total issued share capital stands at 581,327,755 ordinary shares, all of which carry voting rights as the company holds no shares in treasury. This updated share capital and voting rights figure provides a new...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.